Galapagos NV (GLPGF PINK) stock market data APIs
$33.7096
0(0%)
as of February 13, 2026
Try our APIs with
free plan!
Galapagos NV Financial Data Overview
Price chart is built with
Anychart
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Prev. Close
33.7096
Open
33.7096
High
33.7096
Low
33.7096
52 wk Range
22.39-34
Market Cap
3 209 M
Shares Outstanding
65 897 K
Revenue
287 M
EPS
-3.584
Beta
0.095
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Galapagos NV data using free add-ons & libraries
Get Galapagos NV Fundamental Data
Galapagos NV Fundamental data includes:
- Net Revenue: 287 M
- EBITDA: -277 266 240
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-05
- EPS/Forecast: -0.01
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Galapagos NV News
New
Galapagos Receives Transparency Notification from Bank of America
Galapagos NV Mechelen, Belgium; February 16, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from Bank of America. Pursuant to ...
Galapagos Receives Transparency Notifications from Bank of America
Galapagos NV Mechelen, Belgium; February 10, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) received transparency notifications from Bank of America. Pursuant to B...
Third Arc Bio Announces $52M Series A Extension to Expand Oncology and Immunology & Inflammation Portfolio
$52M equity adds to previously announced $165M Series A New investor Andreessen Horowitz (a16z) leads the financing with founding investor Omega Funds; additional investors include Life Sciences at ...
Galapagos (ENXTAM:GLPG) Valuation Check After Mixed Results And Ongoing Net Loss
Galapagos (ENXTAM:GLPG) has been drawing attention after a mixed set of fundamentals, with revenue of €286.921m alongside a net loss of €443.873m. This has prompted investors to reconsider how the...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
